RxDoctor Payments Data

Alba Donaghy

Adult Health · Glendale, NYNPI 1710462858

Payments from drug & device makers

$1,210in general payments, 2019–2025

Across 47 payments — averaging $25.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$380
  • Lilly USA, LLC$247
  • Novo Nordisk$192
  • Gilead$122
  • AbbVie$78
  • Novartis$74
  • plus $117 from 3 others

What the payments were for

  • Food & beverage$1,210100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,210 in reported general payments places this provider in the 70th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$15,638
Medicare patients
76
Services billed
208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin78$103,133
OzempicSemaglutide61$86,725
RybelsusSemaglutide35$60,281
EliquisApixaban40$52,117
VascepaIcosapent Ethyl76$45,142
FarxigaDapagliflozin Propanediol37$41,928
DovatoDolutegravir Sodium/Lamivudine12$40,949
TrulicityDulaglutide32$39,541
JanuviaSitagliptin Phosphate25$35,035
JanumetSitagliptin Phos/Metformin Hcl29$30,819
EntrestoSacubitril/Valsartan20$20,944
Diclofenac Sodium55$12,412
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$10,734
XareltoRivaroxaban15$10,372
Breo ElliptaFluticasone/Vilanterol19$7,026

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$192$147,00696 claims
Boehringer IngelheimJardiance$25$103,13378 claims
AstraZenecaFarxiga$380$41,92837 claims
Lilly USA, LLCTrulicity$247$39,54132 claims
NovartisEntresto$74$20,94420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,828 adult health providers in New York.

Other adult health in Glendale

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →